AssayIndex
Growth-hormone axis peptides

GHRP-2

pralmorelin · KP-102 · C45H55N9O6 · monoisotopic 817.4275 Da. The index holds 110 assay reports on this compound across 18 batches from 14 suppliers.

110 reports18 batchesmedian 99.28 %index spec 99.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Hexapeptide, two Trp residues, one 2-naphthylalanine. Elutes at 9.06 min and separates cleanly from GHRP-6 (0.6 min earlier) — useful, because the two are occasionally mislabelled for each other and differ by 55 Da. Purity is high and uninformative; the oxidation ladder is the interesting axis.

Molecular formula
C45H55N9O6
Monoisotopic mass
817.4275Da
Average mass
817.98Da
Residues
6
Nominal retention (RG-2, 30 min)
9.06min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
0.85 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

029595919887811837 GHRP-29.06 min · 99.28 % 8.70 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative GHRP-2 trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.28 % area at the nominal retention time of 9.06 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 110 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.28% n=110
Interquartile range 0.80pp n=110
Minimum 97.35% n=110
Maximum 99.93% n=110
Pass rate vs spec 74.5% n=110
Median recovery vs claim 98.6% n=53
Median water 4.88% n=110
Median |mass error| 2.5ppm n=96
09182792.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=197.50–97.75 %: n=097.75–98.00 %: n=098.00–98.25 %: n=198.25–98.50 %: n=498.50–98.75 %: n=998.75–99.00 %: n=1399.00–99.25 %: n=2699.25–99.50 %: n=1199.50–99.75 %: n=1499.75–100.00 %: n=31median 99.28 Purity (% area) Reports
Figure 2. Purity distribution across all 110 GHRP-2 records. Dashed line is this compound's median (99.28 %); the solid vertical is the index acceptance specification for the growth-hormone axis peptides class (99.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.197.698.198.699.199.6100.1TFCTFC: Q1 99.54, median 99.76, Q3 99.86, n=23n=23SIGSIG: Q1 98.95, median 99.11, Q3 99.24, n=13outlier 98.51n=13HYBHYB: Q1 99.80, median 99.86, Q3 99.93, n=12outlier 99.57n=12WXTWXT: Q1 98.34, median 98.57, Q3 98.79, n=11outlier 97.35n=11QYBQYB: Q1 98.97, median 99.05, Q3 99.28, n=10n=10GGPepsGGPeps: Q1 99.11, median 99.15, Q3 99.18, n=10outlier 98.75outlier 98.80n=10BCHBCH: Q1 98.50, median 98.77, Q3 98.85, n=9n=9ASYASY: Q1 99.66, median 99.80, Q3 99.92, n=6outlier 99.24n=6HJHJ: Q1 98.93, median 99.12, Q3 99.37, n=4n=4PPGPPG: Q1 99.49, median 99.68, Q3 99.80, n=4n=4HomopeptideHomopeptide: Q1 99.68, median 99.76, Q3 99.84, n=2n=2JEEPJEEP: Q1 99.89, median 99.91, Q3 99.92, n=2n=2MKMMKM: Q1 98.97, median 99.14, Q3 99.31, n=2n=2SSASSA: Q1 99.07, median 99.11, Q3 99.16, n=2n=2 Purity (% area)
Figure 3. GHRP-2 purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
oxidised Trp (+16 Da)-0.36+15.99594%0.190.95
[D-2-Nal]-epimer-0.14mass-identical89%0.120.51
C-terminal free acid (+1 Da)+0.16+0.98488%0.071.16
des-Lys (−128 Da)-0.24-128.09587%0.150.87

Degradation pathways

  • Trp oxidation
  • C-terminal amide hydrolysis

Full impurity profile, with what each named species implies about the synthesis →

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q31598.6197.35–99.87
2024-Q41199.1498.75–99.23
2025-Q13599.7999.32–99.93
2025-Q22n<399.02–99.21
2025-Q30n<3—
2025-Q41499.2798.78–99.93
2026-Q11098.8198.32–99.93
2026-Q21099.6798.57–99.93
2026-Q31399.1198.51–99.57

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent GHRP-2 records of 110.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-043535SIGSIG-2603-6031Janoshik2026-Q399.121.26105.7Buyer-sourced0PASS
AX-2026-043541SIGSIG-2603-6031PeptideMeter2026-Q399.062.08107.4Buyer-sourced1MARGINAL
AX-2026-043539SIGSIG-2603-6031Janoshik2026-Q398.951.74100.4Buyer-sourced1FAIL
AX-2026-043534SIGSIG-2603-6031Medutest2026-Q399.112.1589.8Buyer-sourced1MARGINAL
AX-2026-043542SIGSIG-2603-6031VendorInvestigate2026-Q399.051.43—Buyer-sourced1FAIL
AX-2026-043543SIGSIG-2603-6031Janoshik2026-Q399.381.7098.6Buyer-sourced0PASS
AX-2026-043544SIGSIG-2603-6031PeptideMeter2026-Q399.571.51105.4Buyer-sourced0PASS
AX-2026-043538SIGSIG-2603-6031Kestrel2026-Q398.931.72—Buyer-sourced0FAIL
AX-2026-043536SIGSIG-2603-6031Medutest2026-Q399.171.41—Buyer-sourced0PASS
AX-2026-043540SIGSIG-2603-6031PeptideMeter2026-Q398.601.36—Buyer-sourced1FAIL
AX-2026-043532SIGSIG-2603-6031PeptideMeter2026-Q399.241.24—Buyer-sourced0PASS
AX-2026-043537SIGSIG-2603-6031Janoshik2026-Q399.312.16—Buyer-sourced0PASS
AX-2026-043533SIGSIG-2603-6031Janoshik2026-Q398.511.1392.1Buyer-sourced0FAIL
AX-2026-041817ASYASY-{CAT}-2426VendorInvestigate2026-Q299.936.25105.2Buyer-sourced0PASS
AX-2026-041815ASYASY-{CAT}-2426VendorInvestigate2026-Q299.246.32—Buyer-sourced0PASS
AX-2026-042548HJHJ-2602-W6219Janoshik2026-Q299.181.3191.3Buyer-sourced0PASS
AX-2026-042546HJHJ-2602-W6219PeptideMeter2026-Q299.051.2289.1Buyer-sourced1MARGINAL
AX-2026-042394HomopeptideHOMO-2602-E3918Janoshik2026-Q299.934.41—Buyer-sourced1MARGINAL
AX-2026-042547HJHJ-2602-W6219PeptideMeter2026-Q298.572.00104.4Buyer-sourced0FAIL
AX-2026-041818ASYASY-{CAT}-2426Medutest2026-Q299.896.1893.2Buyer-sourced1FAIL
AX-2026-041814ASYASY-{CAT}-2426Kestrel2026-Q299.936.07—Buyer-sourced0PASS
AX-2026-041816ASYASY-{CAT}-2426Janoshik2026-Q299.646.4590.1Buyer-sourced0PASS
AX-2026-041819ASYASY-{CAT}-2426Janoshik2026-Q299.716.84104.4Buyer-sourced0PASS
AX-2026-043458BCHBCH-2508-M4472Janoshik2026-Q198.775.43—Buyer-sourced0FAIL
AX-2026-042580HJHJ-2512-X6599Janoshik2026-Q199.933.73—Laboratory-retained1MARGINAL